Astaxanthin Treatment Decreases Pro‐Inflammatory Cytokines and Improves Reproductive Outcomes in Patients With Polycystic Ovary Syndrome Undergoing Assisted Reproductive Technology: A Randomized Clinical Trial Publisher Pubmed



Fereidouni F¹ ; Kashani L² ; Amidi F¹ ; Khodarahmian M^{1, 2} ; Zhaeentan S¹ ; Ardehjani NA¹ ; Rastegar T¹ Show Affiliations
Source: Inflammopharmacology Published:2024

Abstract

Research question: In a randomized, triple-blind, placebo-controlled clinical trial (RCT), we investigated the effect of astaxanthin (AST) on pro-inflammatory cytokines, oxidative stress (OS) markers, and assisted reproductive technology (ART) outcomes in 44 infertile Polycystic Ovary Syndrome (PCOS) patients. Design: Patients with PCOS were randomly divided into two groups. The intervention group received 6 mg AST, and the control group received placebo daily for 8 weeks. Blood samples were obtained from all patients before and after intervention and follicular fluid (FF) was collected during the ART procedure. Interleukin (IL) ‐6, IL‐1β were evaluated from serum samples and FF and OS markers (malondialdehyde [MDA], catalase [CAT], superoxide dismutase [SOD], and reactive oxygen species [ROS]) were measured from FF. The groups were compared for ART outcomes as well. Results: A significant decrease in IL-6 and IL-1β concentrations (both, P = < 0.01) serum levels was found following AST treatment. FF cytokine levels and OS markers did not differ significantly between the groups. Reproductive outcomes, including the number of oocytes retrieved (P = 0.01), the MII oocyte count (P = 0.007), oocyte maturity rate (MII %) (P = 0.02) and number of frozen embryos (P = 0.03) significantly improved after intervention. No significant differences were found in chemical, clinical and multiple pregnancies between the groups. Conclusions: AST pretreatment may modify inflammation and improve ART outcomes in PCOS infertile patients. Further investigations are recommended to verify these findings. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.